ticker nerd logo
ImmunoGen Inc

ImmunoGen Inc Stock Forecast & Price Prediction

Live ImmunoGen Inc Stock (IMGN) Price
$31.23

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$31.23

P/E Ratio

-35.49

Volume Traded Today

$0

Dividend

Dividends not available for IMGN

52 Week High/low

31.25/3.61

ImmunoGen Inc Market Cap

$8.72B

🛑 Alert: These ten stocks could have higher potential than $IMGN 🛑

Before you buy IMGN you'll want to see this list of ten stocks that have huge potential. Want to see if IMGN made the cut? Enter your email below

IMGN Summary

From what 0 stock analysts predict, the share price for ImmunoGen Inc (IMGN) might decrease by 100% in the next year. This is based on a 12-month average estimation for IMGN. Price targets go from $ to $. The majority of stock analysts believe IMGN is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

IMGN Analyst Ratings

ImmunoGen Inc has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that ImmunoGen Inc will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

IMGN stock forecast by analyst

These are the latest 20 analyst ratings of IMGN.

Analyst/Firm

Rating

Price Target

Change

Date

Data Not Found!

IMGN Company Information

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
IMGN
ImmunoGen Inc (IMGN)

When did it IPO

1989

Staff Count

277

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Mark Joseph Enyedy

Market Cap

$8.72B

ImmunoGen Inc (IMGN) Financial Data

In 2023, IMGN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IMGN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $287.6M
  • Operating Margin TTM 22.9%
  • Gross profit TTM $108.6M
  • Return on assets TTM -8.5%
  • Return on equity TTM -19.9%
  • Profit Margin -25.6%
  • Book Value Per Share 2.06%
  • Market capitalisation $8.72B
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • Revenue for 2023 N/A
  • EPS this year (TTM) $-0.28

ImmunoGen Inc (IMGN) Latest News

No news data available.

...

IMGN Frequently asked questions

The highest forecasted price for IMGN is $ from at .

The lowest forecasted price for IMGN is $ from from

The IMGN analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.